Quantcast

Industry news that matters to you.  Learn more

Caris Life Sciences Launches Caris Target Now Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary

Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now™ Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the original Caris Target Now comprehensive molecular profiling service offering for all solid tumors.

Affymetrix Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests

Affymetrix, Inc. (NASDAQ:AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer

Abbott announced today it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.

Horizon and UK NEQAS ICC Announce Partnership to Improve Accuracy of Lung Cancer Diagnostic Testing

Horizon Diagnostics (HorizonDx), a division of Horizon Discovery, a leading provider of research tools to support the development and prescription of personalized medicines, recently announced it has signed a strategic partnership agreement with UK NEQAS. The partnership will focus on the development of genetically defined reference standards for novel lung cancer biomarkers.

Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems

Ventana Medical Systems Inc., a member of the Roche Group, and Advanced Cell Diagnostics Inc. (ACD), announced today they have entered a worldwide co-promotion agreement for the first commercially available, fully automated RNA in situ hybridization (ISH) assay system capable of robust detection and visualization of virtually any expressed gene in routine clinical specimens at single-molecule sensitivity.